

Anemias

Dr. Isam Haddadin

Pediatric Hematologist/Oncologist

Amman-Jordan

July,2023

Anemia is defined as a reduction of the red cell volume or hemoglobin conc. Below the range of the values for age occurring in healthy person.

Classification of Anemias

1. Inadequate intake

2. Production(Bone Marrow)

3. Hemolytic Anemias

4. Blood Loss

Inadequate intake

1. Deficiency of specific factors

a. Iron def.

b. Vit. B12

c. Folic acid

Production

1. Congenital pure red cell Anemia

2. Anemia of infection

a. Renal failure

b. Cancer

3. Ineffective Erythropoiesis

Cong.D.A

Hemolytic Anemias

RBC defects : Spherocytosis
Elliptocytosis

Enzyme defects : G6PD
pyruvate kinase

Defect in synthesis of Hb : HbS , C , D , ...
Thalassemia

Immunologic : Rh incompatibility
ABO incompatibility

Physiology of Anemia in infancy

- Newborn : higher Hb
- Physiologic anemia : 2-3 months
- Premature baby : exaggerated anemia

Megaloblastic Anemia

Presence of Megaloblasts in BM and Macrocytes in the blood.

Folic acid def : Inadequate intake,poverty,Goats milk

Absorption-congenital or acquired

Increase Requirement;Hemolysis

Disorder of Metabolism;MTHFR def.

Onset : 4-7 months (infant)

Megaloblastic Anemia


Vit. B12 def. :

- Inadequate intake;Diet or mother
- Defective absorption,Intrinsic factor
- G.I.T;malabsorption,surg,crohn disease
- Defective B12 transport;Cong TCII def
- Acquired; drugs





Age : 9 month – 10 years

Lab : Macrocytic , pancytopenia,hypersegmented neutrophil,Megaloblastic BM

Macrocytes 100x



Hypersegmentation Neutrophil and Nuclear Sticks



Clinical Manifestation

- Failure to thrive
- Generalized Weakness
- Glossitis
- Anorexia
- Pallor
- Jaundice
- Neurologic Manif; Ataxia, paresthesia, hyporeflexia

Treatment of Megaloblastic Anemia

1. Folic acid : 5 mg Tab/day

Higher dose in cong. def.

2. Vit. B12 : 1 mg I.M daily for 2 weeks (if neurologic defect, subacute dorsolateral degeneration of cord), then monthly.

3. Vit. B12: 200-1000 microgm/week x 4 Then monthly

4. Transcobalamin II def; Large doses Vit.12

Case

-A 20 month old girl is brought by her mother to clinic because her physician noticed that the child is pale during her routine check up – she is born at full term and has had no history of bleeding from any site .

Q.1 What are the important elements of history you want to ask ? Mention 3

Answer

1. Detailed nutritional history
2. G.I symptoms , chronic diarrhea
3. Family history of anemia or blood loss

- Q.2 what basic investigations would you like to order ?

- Answer: Hb , PCV , WBC , Plat. , MCV , RDW ,Retic

- If lab. results are : Hb 5 gm

- WBC 6.0

- Plat. 850

- MCV 50

- RDW 20

- Retic 3%

■ Q.3 what's your diagnosis?

Answer

Iron def Anemia

■ Q.4 . what is the first response after therapy why ?

Answer

Increase appetite

Increase activity

Because some enzymes need

Iron

■ Q.5 What is the first change in blood test ?

Answer

Increase Retic after 3-5 days

Case



1. Describe the finding
2. What is the associated anemia in this condition ?

Answer

Brown pigmentation on lips and gum

IDA

Peutz Jeghers Syndrome

Case

A 15 year-old child is evaluated in follow-up for anemia diagnosed during a recent evaluation for symptoms of fatigue. She reports no shortness of breath, dizziness. Medical history is notable only for heavy menses. Family history is remarkable for anemia in her mother. Her only medication is an iron supplement. .

On physical examination, the patient appears well. Temp is 36.9C, BP is 100/60mmHg, HR 80/min . No Lymphadenopathy Spleen is 3cm BCM, and remainder of physical exam is unremarkable.

Laboratory Studies

- Hemoglobin 8.5g/dl
- MCV 68fl
- Platelets count 400,000/microL
- Retic count 6%
- Bilirubin total 2.0mg/dl
- LDH 300U/L
- Ferritin 450ng/ml
- Iron 60MicroG/dl
- TIBC 300 MicroG/dl

- What do you need more?

Hemoglobin electrophoresis

- HbA 92% (slightly low)
- HbA2 4% (increased)
- HbF 4% (increased)
- Hb S 0% (NL)

Question

Which of the following is the most likely diagnosis?

- A. Anemia of chronic disease
- B. Iron malabsorption
- C. Alpha-Thalassemia
- D. Beta-Thalassemia
- E. Iron def. Anemia

Cont. Case

- Answer ; B-Thalassemia Intermedia

Iron def. Anemia


Most common 5.5% among child

Requirement; 2 mg/kg/day

.Peak at 9-24 months

- Inadequate intake; Diet, Breast milk
- Impaired absorption; Celiac
- Blood loss ; G.I; Mice, cow milk allergy, Liver, Lung

Iron Deficiency Anemia 525x



Microcytic,
Hypochromic
Anisocytosis
polychromasia

Tissue Effect Of Iron Def. Anemia

- 1.G.I: Anorexia,pica,atrophic glossitis,dysphagia,Guaiac positive
- 2.CNS: Irritability,fatigue decrease activity,breath holding spells.
- 3.Cardiovascular: Tachycardia,cardiac hypertrophy and H.F
- 4.Immune system: Increase infection,impaired granulocytes killing.

Diagnosis OF Iron Def.

1. History and physical examination;Diet,Family hist,Pallor, No hepatosplenomegaly
2. CBC; Hb,PCV,MCV,MCH,MCHC are low and RDW is >15 .
3. Platelets are increased.
4. Blood Film:Hypoch,Microcytic,Anisocytosis,poikiloct
5. Serum Ferritin <12 ng/ml. Iron level is low
6. Diff Diag: Thalassemia,Lead poisoning,Sideroblastic anemia,Chronic infection,Malignancy

Treatment Of Iron Def

- 1. Diet; fortified with iron milk, Cereals, Vit, C,
- 2. Rx: Oral Ferrous; Dose 6.0mg/kg/day. 3 doses and between meals. Duration for 2-3 month.
- 3. Response: Increase appetite, then Retic count, Hb and the stores.
- 4. Failure to Response: poor compliance
 - Blood loss
 - Inadequate dose
 - Coexistent disease, malabsorption, thyroid, malignancy, VitB12 def.
- 5. Parenteral Rx: Iron Dextran I.M in Bowel disease , no compliance

Hemolytic Anemia :


Evidence of Hemolysis

1. PCV ↓
2. Bilirubin indirect ↑
3. Retic count ↑
4. haptoglobin ↓


Hereditary Spherocytosis

- Aut- Dominant: 75% , Mutation : 25%
- Defect in cell membrane : spectrin ,Ankyrin
- Clinical: Mild HS,Moderate Anemia ,Severe HS 10%
Splenomegally,Gall stones .
- Lab: Low PCV,MCV High MCHC,RDW,Retic.Spherocytosis
Osmotic Fragility test positive .Flowcytometry high sensitive and specific for diagnosis
- Present at newborn as Hemolytic Anemia, Jaundice
- Management ; Blood transfusion, splenectomy

Spherocytes




Hereditary Elliptocytosis



G6PD Glucose-6-phosphate Dehydrogenase Deficiency

- X-linked , more in male
- Most common RBC enzyme defect
- Hemolysis with oxidant stress(infection,drugs,fava beans)
- Drugs ; Asprin , Sulfa , Nitrofurantion,
- Hb precipitation,RBC membrane damage leading to premature red cell destruction.
- .Mediterranean type Severe. Others like US usually moderate.
- .Lab: Evidence of hemolysis
- .Management:Obtain sample,Remove Oxidant,Transfusion

Heinz Bodies



- Heinz bodies are denatured globin, and represent the end-product of oxidative degradation of haemoglobin.
- Presence of stained inclusions **close to the red cell membrane** (Heinz bodies).

Immune Hemolytic Anemia

Extracorpuscular H.A

- Isoimmune; Rh-Incomp. And ABO- Incomp.
- .Autoimmune: Idiopathic-----IgG warm Ab
IgM cold Ab.
Secondary-----Infection;EBV,CM
Drugs---Cephalosp,Penicillin
Malignancy---Lymphoma
- Lab:CBC, Retic , Coombs test,Spherocytes.
- Treatment: Steroid
Transfusion
IVIG
Splenectomy
Immunotherapy

Hematological Manifestation Of Systemic Diseases

- Results from:
- 1. BM dysfunction—Anemia, Polycythemia
- Thrombocytopenia, Leukopenia, Leukocytosis
- 2. Hemolysis
- 3. Immune Reaction
- 4. Altered in Hemostasis, Inhibitors to factors

Hematologic Manif. Cont...

1. Heart: Prosthetic valves—Thrombocytopenia
Anemia due to hemolysis, Iron def.
2. G.I.T: Reflux, Stomach(Vit.B12), Celiec,
Bowel disease, Bleeding(Mickles)
3. Liver: Hypersplenism, Wilson disease
Shortened RBC survival, Bleeding.
4. Renal: Erythropoeitin, Uremia, Blood loss
Dialysis, RBC survival decreased.
5. Chronic Illness: Decrease Fe flow from RES.
6. Skin: Dyskeratosis Congenita, Eczema

Case

A one month old baby was referred because of anemia and jaundice since birth, he received 3 times blood transfusion since that time. On examination he is pale, mild jaundiced, no dysmorphic features, spleen 2cm below costal margin.

Q1. what are the differential diagnosis of his anemia?

Answer

1. ABO incompatibility
2. Rh incompatibility
3. G6PD def.
4. Infection
5. Spherocytosis
6. Alpha thalassemia

The mother blood group is AB+

The baby blood group is B+

Hb of baby : 10 gm

Bilirubin : 22mg, direct : 2mg at age of 5 days

Blood film: spherocytes

Test to do ??????

Family history: 3 siblings normal and no similar condition.

Q1: what is your most likely diagnosis?

Answer

Do minor group Rh C and E

Result: baby Rh E+

mother Rh E-

What is the treatment?

Answer

To give :Rh E negative blood
phototherapy for jaundice
IV Ig

Question

Persistent Reticulocytosis in a newborn baby suggest the presence of all the following except;

A. Hypoxia

B. Blood loss

C. Hypoglycemia

D. Fetoplacental blood transfusion

E. ABO blood group incompatibility

Answer

C. Hypoglycemia

Question

Each of the following Rh antigens have been implicated as causes of significant hemolytic disease of the fetuses and newborn except one;


- A. D antigen
- B. d antigen
- C. E antigen
- D. e antigen
- E. c antigen

Answer

B. d antigen

Thalassemia

Introduction:



Beta thalassemia major affects 60000 births per year worldwide. A mutation in the B-globin gene causes defective erythropoiesis ,which in its homozygous form results in a severe anemia ,rendering the individual dependent on lifelong blood transfusions .

Long term survival remains poor ,with data from UK showing 50% of patients dead by the age of 35 years

Major Classification of Thalassemia

■ Alpha Thalassemia



■ Beta Thalassemia

■ 4-genes

(~ 600 mutations)

■ 2-genes (25 mutations)

(~80% of mutations)




Chances to have Thalassemia

- If both parents are Thalassemia Carriers

25% chance of contracting thalassemia major

50% chance of contracting thalassemia minor

25% chance of being Normal



Types of Hb

1.Hb Gower 1; 2 zeta,2 epsilon

2.Hb Gower 2 ;2 alpha, 2 epsilon

3.Hbf ;2 alpha,2 gama

4.Hb A1 ; 2 alpha, 2 beta

5.Hb A2 ; 2 alpha, 2 delta

Globin

4; Alpha globin genes on chromosome 16

2; Beta, Gamma, Delta globin genes on chr. 11

Ratio of HbA1/HbA2=30/1

Thalassemia Major

Clinical

- -Chronic hemolytic anemia
- -Skeletal deformities
- -Splenomegaly
- -Heart failure
- -Iron overload
- -Gall stones
- -Growth impaired

B-Thalassemia

- Lab:1. Microcytosis,Hypochromia.Anemia , Target cell.
- 2.Hb-electrophoresis ; HbF increased
Hb A1 decrease
Hb A2 normal
- Normal values: Hb A1 95%
HbA2 2-3.5%
Hb F 1%

B-Thalassemia

- Treatment:
- 1.Chronic Blood Transfusion.
- 2.Folic Acid.
- 3.Chelation Therapy.
- 4.Splenectomy.
- 5.BMT.

Alpha Thalassemia

1. Silent carrier ; 1 gene deletion ■
2. Alpha-Thalassemia Trait ; 2 genes deletion ■
3. HbH disease (B4) ; 3 genes deletion ■
4. Hydrops Fetalis ; 4 genes deletion ■

Prevention of Thalassemia

1. Identification of carriers (long Term prevention)

2. Genetic counselling of families with known Thalassemia “Clinical” for couples at risk before marriage (practical term of prevention)

3. CBC for Couples;

If MCV less than 78 ,do Hb-electroph. to role out Thal. Trait.



Prevention of Thalassemia


Prenatal Screening Of Couples at Risk
after Conception (not practical)




Carrier Identification

Standard scheme

1. Peripheral blood count and indices:
(R.B.C, Hb , MCV, MCH, MCHC, RDW)
done by automated counter
2. Hb-electrophoresis





Procedure


Prenatal diagnosis

1. CVS* < 8-12 weeks of gestation.
 2. AFT** > 15 weeks of gestation.
 - Study fetal cells for parent's same mutation of thalassemia minor they have
- * : Chorionic villus sampling
- ** : Amniotic fluid testing



Incidence of Thalassemia world wide (Carrier's)

- -Pakistan: 5.5% (4-7 million estimated carriers)
- -Jordan: 4.5%
- Gaza strip: 3.5%
- -Iran: 3.64% (8000 pregnancies at risk/year)
- -Iraq: 3 million carriers, ? 25000 cases.
- -Sri-lanka : 2.0%, 1000 cases thalassemia major
- -Italy : 8000 cases of thalassemia major



Sickle Cell Anemia

- .Aut.recessive, Valine substituted for Glutamic acid in the No.6 position of B chain.
- .Sickle cell Trait has benign clinical course
- .8 % American blacks have the trait.
- .HbS about 40%. Severe hypoxia may produce Vaso-occlusive phenomena.
- .Carriers should avoid hypoxia.



Sickle Cell Anemia

Sickle Cell Disease: Homozygous for the gene
.Presentation until one year of age.

Clinical Manifestation:

- 1.Painful Vaso-occlusive crises; Hands,Feets
- 2.Strokes due to cerebral occlusion.
- 3.Acute Chest Syndrome.
- 4.Sequestration crises, pooling of blood in spleen and liver—State of shock.
- 5.Aplastic crises ,Parvovirus.
- 6.Sepsis; capsulated organism

Sickle CELL

- Lab: Hb 5-9gm/dl.

Spontaneous sickling, Target cells

Retic 5-15%, Bil increased,

Howell Jolly bodies

Sickling test .

Hb-electroph; HbS 90 %

Hb F 2-10%

Hb A 0%


Hb A2 2.5%

Sickle Cell Anemia

Boat Cells

Sickle cells

Target Cell



Sickle-Thalassemia

A microscopic view of peripheral blood in sickle-thalassemia. The field is dominated by numerous small, red blood cells (microcytosis) with a high hemoglobin concentration. A few sickle-shaped cells are visible, which are characteristic of sickle cell disease. The overall appearance is that of a mild anemia with sickle cells.

Peripheral blood: S-thalassemia- In Sickle-thalassemia, the anemia tends to be milder than in SS disease, there are few sickle cells, and there is microcytosis. 640x

Sickle cell Treatment

1. Therapy during episodes
2. Tonics: Folic acid.e
3. Analgesics: Paracetamole, Codeine, Morphine
4. Antibiotics; Penicillin, Vaccin
5. Hydration during crises
6. Blood Transfusion not always, Exchange Transfusin in Acute chest syndrome
7. Splenectomy in hypersplenism or sequestration.
8. Hydroxyurea.
9. BMT; in certain cases


Hypertransfusion Protocol :

Hb level 10.5 gm (pretransfusion level)

- 1. Maximizing growth and development**
- 2. Minimizing extramedullary hematopoiesis and decreasing skeletal abnormalities**
- 3. Reduce iron absorption from gut**
- 4. Reduce splenomegaly and hypersplenism**

Iron overload

1. Ongoing transfusion therapy
2. Increase gut absorption of iron
3. Chronic hemolysis



Chelation Therapy

The objectives are :

- 1.To bind free extracellular iron**
- 2.To remove excess intracellular iron**
- 3.To attain a negative iron balance (i.e, iron excretion > iron input)**

Iron Chelating Agents

Desferal

1. Iron binding efficiency 1:1
2. Iron selectivity is high
3. Regimen Sc or iv infusion
4. Dose 40mg/kg
5. Safety: good, poor compliance

Iron Chelating Agents

Ferriprox

1. Binding 3:1

2. Iron selectivity some report of zinc def.

3. Regimen : oral, three times daily

4. Safety neutropenia, joint problems

5. Dose 75mg/kg

Iron Chelating Agents

Deferasirox (Exjade)

1. Iron binding 2:1
2. Iron selectivity highly selective
3. Regimen oral, once daily
4. Safety skin rashes, kidney toxicity
5. Dose 20mg/kg

Case . 5 Year old male child with the following lab data?

- PCV 24%
- WBC 10.0
- P_{Lat} 200
- MCV 80
- Hb – electrophoresis: - H_{bs} 80
 - H_{bf} 15
 - H_{bA2} 3.0

What is the Diagnosis ?

ANSWER

■ *Hbss*

Case . Pt with pallor, found to have:

PCV 24%

WBC 10.0

PLT 200

MCV 65

Hb – electrophoresis: - Hbs 75

- Hbf 18

- HbA2 4.5

What is the Diagnosis ?

ANSWER

■ *Hb SB thalassaemia*

Case . Pt with pallor, found to have :

PCV 24%

WBC 10

PLT. 200

MCV 65

Hb – electrophoresis: - Hbs 70

- Hbf 10

- HbA1 15

- HbA2 4.2

What is the Diagnosis ?

ANSWER

■ *Hb SB+ thalassemia*

Case . Pt with pallor, found to have :

PCV 28%

WBC 9.0

Plat. 200

MCV 80

Hb – electrophoresis: - Hbs 36

- HbA1 60

- HbA2 2.5

■ Asymptomatic

What is the Diagnosis ?

ANSWER

■ *Hb SA*

Case . Pt with pallor, found to have
25%.WBC 5.0 Plat.200

PCV

MCV 69

Hb – electrophoresis: - Hbs 80

- Hbf 15

- HbA2 3.0

What is the Diagnosis ?

ANSWER

- *Hb SS WITH Alfa.
thalassemia*

Question

If one parent is carrier of HbS and the other is a patient with Sickle cell disease HbSS. What are the chances in each pregnancy? ■

Answer

1. HbSS Disease 50%
2. HbS Carrier 50%



Bone Marrow Failure

- Bone marrow failure syndromes include a group of disorders that can be either inherited or acquired. These are disorders of the hematopoietic stem cell that can involve either one cell line or all lines, with hypoplastic or aplastic B.M.

Bone Marrow Failure

- BM failure manifest as isolated one cell line or pancytopenia; quantitative or qualitative failure.
- Single Line RBC:
- 1. Diamond-Blackfan
- 2. Cong. Dyserythropoietic anemia
- 3. Pearson Syndrome
- 4. Acquired; TEC, Drugs, Infection
- Single Line WBC:
- 1. Shwachman Diamond Syndrome
- 2. Kostman Syndrome

BM Failure

- Single Line Platelets:
- 1. Cong. Amegakaryocytic Thrombocytopenia
- 2. TAR Syndrome.
- Failure Of 3 Lines:
- 1. Fanconi Anemia.
- 2. Familial Aplastic Anemia.
- 3. Dyskeratosis Congenita.
- 4. Acquired Aplastic Anemia.


Aplastic anaemia

- Pancytopenia: at least two of anaemia (Hb <10) + neutropenia (<1.5 x10⁹/L) and thrombocytopenia (<50 x10⁹/L)

and

- Hypocellular bone marrow

Normal



Aplastic anaemia



Causes of aplastic anaemia

- Congenital, e.g Fanconi anaemia
- Acquired:
 - idiopathic (80%)
 - viruses: post- hepatitis, EBV, CMV and HIV
 - drugs & chemicals
 - paroxysmal nocturnal haemoglobinuria (PNH)




Mucosal haemorrhage



Buccal haemorrhage

FANCONI'S ANAEMIA : PHYSICAL ABNORMALITIES

<u>ABNORMALITY</u>	<u>%</u>
Skin café-au-lait	76
Microsomy	65
Thumb anomalies	40
Microcephaly	39
Hypogenitalia	33
Renal anomalies	32
Skeletal anomalies	28
Strabismus	23
Hyper-reflexia	20
Microphthalmia	19
Mental retardation	18
Cong. heart disease	7





Management of Aplastic Anemia

- Steroid
- Androgen
- ATG + cyclosporine
- BMT

Transfusion in Aplastic Anemia

.Blood:Packed RBC 10-15 ml/kg.

Side Effect:

- 1.Allergy
- 2.Fever;Non-hemolytic febrile reaction.
- 3.Transmission of Viruses
- 4.Hemolytic Reaction.
- 5.Transfusion GVHD.

Platelets Transfusion

BMT in Thalassemia

leukemia. History :first BMT was done
1969 in

first BMT in Thalassemia was
reported
in USA by Thomas 1981.

First report of BMT in Thalassemia

Problems: 1.Rejection

2.Regimen toxicity

Risk factors in Thalassemia

(pesaro classification)

1.Hepatomegaly

2.liver fibrosis

3.Quality of chelation

BMT in Thalassemia

The finding of a suitable related donor:

25% in Thalassemia

20% in sickle cell

Indication of BMT

- 1- Severe Aplastic anemia.**
- 2- CML**
- 3-AML in CR1 or CR2**
- 4-ALL in CR2**
- 5-SCID**
- 6-B-Thalassemia**
- 7- Lymphoma with relapse**

Types Of BMT

1. Allogenic BMT
2. Peripheral Stem Cell Transplantation
3. Matched Unrelated Donor
4. Human Umbilical Cord Blood Transplant
5. Autologous BMT

THANK YOU

